Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065920 | 0.86 | GPR119 (0.55) | PIK3CDGPR119NPBWR1MCHR1 | |
| SCHEMBL13734463 | 0.85 | GPR119 (0.59) | PIK3CDGPR119 | |
| SCHEMBL13357777 | 0.85 | GPR119 (0.48) | PIK3CDGPR119 | |
| SCHEMBL288499 | 0.85 | GPR119 (0.41) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL12236466 | 0.85 | GPR119 (0.55) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL288503 | 0.84 | GPR119 (0.57) | GPR119 | |
| SCHEMBL12320310 | 0.83 | GPR119 (0.58) | PIK3CDGPR119 | |
| SCHEMBL12276897 | 0.83 | GPR119 (0.58) | PIK3CDGPR119 | |
| SCHEMBL3258302 | 0.83 | GPR119 (0.47) | PIK3CDGPR119 | |
| SCHEMBL17456002 | 0.80 | POLB (0.52) | PIK3CDGPR119NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2382203-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8410122-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410122-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8362248-B2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| EP-1911756-B9 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-1911756-B1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1911756-A2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1732562-B1 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PC, GPR119, PNPO | PIK3CD 1389/4885GPR119 2/4885PIK3CA 1231/4885 |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PLPBP, PNPO, PDXK | PIK3CD 1113/4885GPR119 7/4885PIK3CA 697/4885 |
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, BDKRB2 | PIK3CD 1619/4885GPR119 1/4885PIK3CA 2043/4885 |
| US-20060155128-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PNPO, PLPBP, FPGS | PIK3CD 1322/4885GPR119 10/4885PIK3CA 957/4885 |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | GPR119, SLC5A2, SLC5A1 | PIK3CD 342/4885GPR119 1/4885PIK3CA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.